bioAffinity Tech released FY2024 9 Months Earnings on November 14 EST, with actual revenue of USD 7.154 M and EPS of USD -16.3396

Brief Summary

bioAffinity Tech reported 2024 Q3 revenue of 7.15 million USD and an EPS of -16.3396 USD.

Impact of The News

bioAffinity Tech’s Q3 financial results show a significant net loss with an EPS of -16.3396 USD, indicating the company is facing substantial profitability challenges. The company’s revenue for the quarter stood at 7.15 million USD. To provide some context, the company underperformed compared to its peers such as Tencent and Shopify, which reported higher revenue growth and profitability. Tencent achieved a total revenue of 167.2 billion RMB with an 8% YoY growth, and Shopify posted a quarterly revenue of 2.162 billion USD with a 26.14% YoY increase .

The large negative EPS reflects substantial operational challenges or high expenditures, which could be due to several factors such as ongoing R&D investments, marketing expenses, or other operating costs. Compared to other firms in the tech and healthcare sectors, such as Medtronic with a PS ratio of 3.49 and Intuitive Surgical with a PS ratio of 22 , bioAffinity Tech’s revenue and profitability are currently lagging.

Moving forward, the company’s financial health may depend on its ability to either increase revenue through market expansion, product launches, or strategic partnerships or reduce costs to improve margins. Investors should closely monitor the company’s upcoming quarterly reports and strategic initiatives to gauge potential turnaround or further financial deterioration.